Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024

世界におけるバイオシミラー及び後続生物製剤市場(2014-2024)

◆タイトル:Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024
◆商品コード:Visiongain-4052662
◆調査・発行会社:visiongain
◆発行日:2014年5月
◆ページ数:263
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single user licence(1名使用)GBP1,799 ⇒換算¥269,850見積依頼/購入/質問フォーム
Dept Licence(部署内共有可)GBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site Licence(同一国内社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界におけるバイオシミラー及び後続生物製剤市場(2014-2024)"について調査・分析し、エグゼクティブサマリー、市場動向、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、セグメント別市場分析、専門家の見解、結論などの情報をお届けいたします。

Biosimilar drugs – discover trends and segments with highest potential revenues
Do you want to find sales potentials of biosimilars? Visiongain’s updated report gives you revenue predictions for those biological drugs from 2014, helping you stay ahead. For those therapies you find financial data, R&D trends, opportunities and selling prospects.

In that new analysis you get sales forecasts to 2024 at overall world market, therapeutic class, molecule and national level. You also assess trends, technologies and expected products, benefiting your reputation for technological, clinical and commercial insight.

Developments in that industry – see what’s possible for those biotech medicines
There you explore what the future holds for biosimilars (follow-on biologics, follow-on protein products). So read on to investigate that industry and hear what future sales it could achieve.

Forecasts and other analyses explain the best financial prospects
In our study you find revenue forecasting to 2024, historical results, growth rates and market shares. There you get quantitative and qualitative analysis, business news and research and development (R&D). You also gain 104 tables, 76 charts and two company interviews.

Many opportunities exist for those competitors of original biological drugs (biologics). You discover segments most likely to prosper. Finding data you need just got easier. There help your research, analyses and plans, increasing your chances of success.

And the following sections show how you benefit from that new analysis.

Predictions for that world market and its submarkets
Along with revenue prediction for the overall world market for biosimilars, our work shows forecasts to 2024 for its individual submarkets:
• Monoclonal antibodies (mAbs) and fusion proteins (FPs) – including rituximab, infliximab, trastuzumab, adalimumab and etanercept segments
• Insulins – inc. submarkets of human insulin and analogues, as well as insulin glargine and insulin lispro
• Erythropoietins (EPO)
• Granulocyte colony-stimulating factors (G-CSF)
• Interferons – inc. alpha and beta segments
• Growth hormones (hGH, somatropin)
• Fertility hormones

That report shows you revenue potentials of those biopharmaceuticals, helping you find chances to develop your business. Also benefit your authority on those treatments.

Our investigation also discusses what stimulates and restrains sales of those subsequent entry biologics. You explore that industry, seeing what products can achieve the most success.

Comparisons of biosimilar drug sales with those of the overall biologics market
You also discover revenues to 2024 for the overall biologics market and its segments. There find how the biosimilars market compares at world level. See how market share can expand.

Our study also divides its forecasting into geographical regions.

National markets for those therapeutic proteins – where will highest sales and growth occur?
Developments worldwide will influence that follow-on biologics market, raising demand for biosimilars in developed and developing countries. See how and where.

Our analyses show you individual revenue forecasts to 2024 for 12 national markets and one regional block:
• United States (US)
• Japan
• European Union (EU) and leading members – Germany, France, UK, Italy and Spain
• BRIC nations – Brazil, Russia, India and China
• South Korea.

There you discover progress and outlooks. You assess the biosimilar industry’s future – hear about developments and find their significance. Our work explains, exploring issues.

Forces affecting that biopharmaceutical industry and market
That new report discusses issues and events affecting the industry and market from 2014, including these developments:
• Considerations for developing biosimilars – challenges and opportunities
• Guidelines from regulators and what they mean for developers and producers
• Needs and challenges in developing biosimilar mAbs
• Developments in technology to aid biosimilar drug production
• Collaborations among companies for making those biopharmaceutical molecules.

That study also discusses other aspects of those biotech drugs, including these:
• Incidence and prevalence of diseases affecting treatment needs
• Economics stimulating demand for substitute biological medicines
• Biobetters as rivals of biosimilars
• Patent challenges and data exclusivity for biopharmaceuticals
• Outsourcing to gain expertise in pharma biotechnology and production efficiencies.

There you assess that industry’s strengths, weaknesses, opportunities and threats (SWOT), also exploring social, technological, economic and political questions. And you get Porter’s Five Forces analysis. So you gain feel for that sector and its progress.

Discover, then, what the future holds, benefiting your reputation for commercial insight.

Companies and 2018 market value – what’s possible?
From 2014, product launches there hold great potential for investments, uptake and sales. Our study predicts the world market for biosimilars and related follow-on biologics will reach $9.2bn in 2018, and multiply in size to 2024. See how high revenues can go.

You assess there what biosimilar technologies, products types and companies hold most potential. Our analyses cover these firms and many other developers, producers and sellers:
• Sandoz (Novartis)
• Hospira
• Mylan
• Pfizer
• Merck & Co.
• Boehringer Ingelheim
• Dr. Reddy’s Laboratories
• Teva Pharmaceutical Industries.

In our report you find 245 organisations mentioned. You also get interviews with authorities in the industry. Hear what shapes it, discovering what participants say and do.

From this decade there will arise many sales opportunities. Prospects for those rivals of established biologics are strong. See what holds greatest potential. Our work shows you technological and commercial possibilities for those substitutes, helping you stay ahead.

Ways Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 helps
In particular, then, our investigation gives you the following knowledge to benefit your work:
• Revenues to 2024 at overall world level and for biological drug and biosimilar submarkets – assess outlooks for production, marketing and sales
• Forecasts to 2024 for 12 national markets in the Americas, Europe and Asia – appraise developed and developing countries for potential revenues
• Prospects for established competitors and rising companies – explore portfolios, results, R&D, opinions from interviews and outlooks for success.

Data there found nowhere else, benefiting your authority on pharma biotechnology
That work gives independent analysis. There you receive business intelligence found only in our report, seeing where prospects are most rewarding.

With our study you’re less likely to fall behind in information or miss opportunity. See there how you can benefit your searches, analyses and decisions, also saving time and helping your influence.

Our new investigation is for everyone assessing the present and future of biological drugs. There you find data, trends, opportunities and sales predictions. So please get that report here now.

【レポートの目次】

1. Executive Summary
1.1 Biosimilars: World Market Review 2014
1.2 Report Contents
1.2.1 Benefits of this Report
1.3 Report Methods
1.3.1 Financial Information in this Report
1.3.2 Who is this Report for?
1.4 An Introduction to Biosimilars and Biosimilar Drug Development
1.4.1 A Brief History of Biological Drug Development
1.4.2 The Advent of Biosimilars
1.4.2.1 What Is a Biosimilar?
1.4.3 What Is Driving Demand for Biosimilar Development?
1.4.4 What Has Slowed Biosimilar Drug Development?
1.4.5 Important Sectors of the Biosimilar Market

2. The World Biosimilars Market: Outlook and Forecast 2014-2024
2.1 The World Biosimilars Market 2013
2.1.1 Biosimilars as a Share of the Biologics Market, 2013
2.1.2 Eleven Drugs Account for More than 50% of Biological Drug Revenues
2.1.3 Leading Biologics Sectors Represent Leading Targets for Biosimilars
2.2 Outlook for the World Biosimilars Market 2014-2024
2.2.1 Revenue Growth in the Biologics Market 2014-2024
2.2.2 Biosimilars Market Forecast 2014-2024
2.2.3 Changing Market Shares for Leading Segments 2014-2024
2.2.4 What Will Drive Growth in the Biosimilars Market to 2024?
2.2.5 Biosimilars Market Restraints, 2014-2024

3. Biosimilars in Leading Developed Markets 2014-2024
3.1 Which Were the Leading National Submarkets for Biosimilar Sales in 2013?
3.1.1 Growth in Leading Developed Markets to 2024
3.2 The Outlook for Biosimilars in the US 2014-2024
3.2.1 When Will Finalised FDA Development Guidelines be Released?
3.2.1.1 A Fourth Draft Guideline Released in 2013
3.2.2 US States Introduce their Own Biosimilar Rules
3.2.3 US Biosimilars Submarket Forecast, 2014-2024
3.2.3.1 What Rates of Uptake Can We Expect for Biosimilars in the US?
3.3 Biosimilars in the EU: Outlook 2014-2024
3.3.1 The EU Led the World in Biosimilar Regulation
3.3.2 The EMA Updates its Overarching Guidelines 2012-2014
3.3.3 Biosimilar Uptake in the EU 2008-2013
3.3.4 The EU Biosimilars Submarket Forecast 2014-2024
3.3.4.1 Biosimilar MAbs in the EU from 2014
3.3.5 Biosimilars in Germany: High Uptake for Current Biosimilars
3.3.5.1 German Biosimilars Submarket: Revenue Forecast 2014-2024
3.3.6 The French Biosimilars Submarket 2014-2024
3.3.6.1 New Rules Introduce the Possibility of Biosimilar Substitution
3.3.6.2 French Biosimilars Submarket Forecast 2014-2024
3.3.7 Biosimilars in the UK: High Uptake for Filgrastim
3.3.7.1 UK Biosimilars Submarket Forecast 2014-2024
3.3.8 The Italian Biosimilars Submarket Forecast 2014-2024
3.3.9 Outlook for Biosimilars in Spain: Submarket Forecast 2014-2024
3.4 The Japanese Biosimilars Submarket 2014-2024
3.4.1 Biosimilar Regulation in Japan 2014
3.4.1.1 Differences Exist Between EU and Japanese Guidelines
3.4.2 Collaboration Agreements Drive Biosimilar Development in Japan
3.4.3 Biosimilar MAbs Could be Launched in 2014
3.4.4 Japanese Biosimilars Submarket Forecast 2014-2024

4. Outlook for Biosimilars in Emerging Markets 2014-2024
4.1 China and India Lead in Biosimilar Range and Revenues 2014
4.1.1 Biosimilar Growth in Emerging National Markets 2014-2024
4.2 Outlook for the Chinese Biosimilars Submarket 2014-2024
4.2.1 Biosimilar Development Guidelines Set for Release
4.2.2 Biosimilars Account for Less than Half of Biotech Revenues in China
4.2.3 Chinese Biosimilars Submarket Forecast 2014-2024
4.3 Biosimilars in India: Regulatory and Commercial Outlook 2014-2024
4.3.1 CDSCO Guidelines Released in 2012: How will they Affect Developers?
4.3.2 Biosimilar Uptake in India 2014
4.3.3 Strong Growth Forecast for the Indian Biosimilars Submarket 2014-2024
4.4 The Brazilian Biosimilars Submarket 2014-2024
4.4.1 Biosimilar Regulations Are Similar to those in the EU
4.4.2 Promoting Domestic Biosimilar and Biologic Development
4.4.3 Brazilian Biosimilar Submarket Forecast 2014-2024
4.5 What Potential is there for Biosimilars in Russia to 2024?
4.5.1 No Specific Guidelines for Biosimilar Development
4.5.2 Russian Biosimilars Submarket Forecast 2014-2024
4.6 South Korea: A Leading Country for Biosimilar Development
4.6.1 Established Biologic and Biosimilar Guidelines
4.6.2 Local Players Are Keen on Biosimilar MAb Development
4.6.3 South Korean Biosimilars Submarket Forecast 2014-2024

5. Biosimilar Monoclonal Antibodies and Fusion Proteins: Submarket Forecast and Pipeline 2014-2024
5.1 Monoclonal Antibodies (MAbs): The Largest Biologics Market Sector in 2013
5.1.1 High Demand in Cancer and Autoimmune Disease
5.2 The MAbs Submarket Forecast 2014-2024
5.2.1 Rising Disease Incidence to Stimulate Sales Growth
5.2.2 MAbs: Product and Portfolio Lifecycle Management
5.3 Biosimilar MAbs Outlook 2014-2024
5.3.1 There Are Challenges in Antibody Development and Manufacturing
5.3.2 Partnering to Launch Biosimilar MAbs
5.3.3 Biosimilars MAbs Submarket Forecast 2014-2024
5.3.4 Multiple Product Launches Will Drive Submarket Growth
5.3.5 Biosimilar MAbs and FPs: Submarket Restraints 2014-2024
5.3.6 Leading Targets for Biosimilar Development 2014-2024
5.4 Biosimilar Rituximab 2014-2024
5.4.1 Three Biosimilars Available in 2014
5.4.1.1 Reditux (Dr. Reddy’s Laboratories)
5.4.1.2 Mabtas: A Second Indian Biosimilar
5.4.1.3 Kikuzubam: Removed from the Market, 2014
5.4.2 Biosimilar Rituximab: Revenue Forecast 2014-2024
5.4.3 Biosimilar Rituximab Pipeline 2014
5.4.3.1 A Reduced Late-Stage Pipeline 2012-2014
5.4.3.2 GP2013 (Sandoz): The Most Advanced Developed-Market Candidate
5.4.3.3 BI 695500 (Boehringer Ingelheim)
5.4.3.4 MabionCD20 (Mabion)
5.4.3.5 BCD020 (Biocad)
5.4.3.6 CT-P10 (Celltrion): Development Delayed
5.4.3.7 PF-05280586 (Pfizer)
5.5 Biosimilar Infliximab 2014-2024
5.5.1 Hospira and Celltrion: Biosimilars for Developed Markets
5.5.1.1 Egis Pharmaceuticals Launches Flammegis in Eastern Europe
5.5.2 Biosimilar Infliximab: Revenue Forecast 2014-2024
5.5.3 Biosimilar Infliximab Pipeline 2014
5.5.3.1 BOW-015 (Epirus Biopharmaceuticals)
5.5.3.2 R-TPR-015 (Reliance Life Sciences)
5.5.3.3 Nichi-Iko: A Second Biosimilar for Japan
5.6 Biosimilar Trastuzumab 2014-2024
5.6.1 Biocon/Mylan: Biosimilar Approval in India
5.6.1.1 Roche Sues Biocon and Mylan over Hertraz Launch
5.6.2 Herzuma: Approved in South Korea 2014
5.6.3 Biosimilar Trastuzumab: Revenue Forecast 2014-2024
5.6.4 Biosimilar Trastuzumab Pipeline: Four Clinical-Stage Candidates in 2014
5.6.4.1 Amgen and Actavis Advance to Phase III
5.6.4.2 PF-05280014 (Pfizer): Phase III Launched 2014
5.6.4.3 BCD-022 (Biocad): A Third Phase III Biosimilar
5.7 Biosimilar Adalimumab 2014-2024
5.7.1 Humira is the World’s Leading Antibody Therapy
5.7.2 AbbVie Seeks to Protect its Lead Asset
5.7.3 Biosimilar Adalimumab: Revenue Forecast
5.7.4 First Biosimilar to Launch in India
5.7.4.1 Amgen Advances to Phase III
5.7.4.2 GP2017 (Sandoz)
5.7.4.3 Phase I Biosimilar Adalimumab Candidates
5.8 Biosimilar Etanercept 2014-2024
5.8.1 Enbrel Is the Leading Fusion Protein
5.8.2 Extended Patent Protection in the US
5.8.3 Biosimilars Are Available in Emerging National Markets
5.8.4 Biosimilar Etanercept: Revenue Forecast 2014-2024
5.8.5 Biosimilar Etanercept Pipeline 2014
5.8.5.1 GP2015 (Sandoz)
5.8.5.2 CHS-0214 (Coherus BioSciences)
5.8.5.3 Hanwha Chemical: Submitted in South Korea
5.8.5.4 TuNEX (Mycenax Biotech)
5.9 Other Leading Antibody Targets 2014-2024
5.9.1 Avastin Loses Patent Protection in 2018

6. Biosimilar Insulin Submarket Outlook 2014-2024
6.1 Insulin: The Second-Largest Biological Drug Sector 2014
6.1.1 Insulin Submarket Forecast 2014-2024
6.1.2 Diabetes Prevalence Is Rising Worldwide
6.2 Biosimilar Insulin Submarket 2014-2024
6.2.1 There Are No Biosimilars in Developed Markets in 2014
6.2.2 Biosimilar Insulin Submarket Forecast 2014-2024
6.2.3 Launch of Biosimilar Insulin Analogues to Stimulate Growth from 2014-2024
6.2.4 Biosimilar Insulin Submarket Restraints 2014-2024
6.3 Biosimilar Human Insulin Submarket 2014-2024
6.3.1 A Submarket Restricted to Emerging Markets?
6.3.2 Biosimilar Human Insulin in China
6.3.2.1 Biosimilar Insulin Uptake in China 2014
6.3.3 Biosimilar Human Insulin in India
6.3.3.1 What Share Do Biosimilars Hold of the Indian Insulin Submarket?
6.3.3.2 Indian Developers Target the US and EU?
6.3.4 Biosimilar Human Insulin in Other Emerging Markets
6.3.5 Biosimilar Human Insulin Submarket Forecast 2014-2024
6.4 Biosimilar Insulin Analogues 2014-2024
6.4.1 Insulin Analogues Account for Three Quarters of Global Insulin Revenues
6.4.2 Insulin Glargine Is the Main Biosimilar Target
6.4.3 Biosimilar Insulin Analogue Revenue Forecast 2014-2024
6.4.4 Insulin Market Leaders Are Developing Ultra-Acting Insulin Analogues
6.5 Biosimilar Insulin Glargine 2014-2024
6.5.1 Two Biosimilars Are Available in India
6.5.1.1 Mylan Partners with Biocon for Insulin Analogues
6.5.2 Biosimilar Insulin Glargine: Revenue Forecast 2014-2024
6.5.3 Ultra-Long Acting Insulin Analogues in Development
6.5.4 Biosimilar Insulin Glargine Pipeline 2014
6.5.4.1 Eli Lilly and Boehringer Ingelheim Submit Approval Applications in the EU and US
6.5.4.2 Merck & Co. Partners with Samsung Bioepis
6.6 Biosimilar Insulin Lispro 2014-2024
6.6.1 One Biosimilar Available in 2014
6.6.2 Biosimilar Insulin Lispro Revenue Forecast 2014-2024
6.6.3 Ultra-Rapid Acting Insulin: New Options from 2014
6.6.4 Biosimilar Insulin Lispro Pipeline 2014
6.6.4.1 Insulin Lispro Biosimilars in India

7. Biosimilar Erythropoietins: Future Directions 2014-2024
7.1 Three Products Lead the EPO Therapy Submarket in 2014
7.1.1 Aranesp and Procrit: Falling Revenue 2011-2013
7.1.2 Safety Concerns for Erythropoietin-Stimulating Agents
7.2 EPO Submarket Forecast 2014-2024
7.2.1 The Challenge from Oral Therapies Is Coming
7.2.2 Prevalence of Chronic Kidney Disease Will Rise 2014-2024
7.3 The Biosimilar EPO Submarket 2014-2024
7.3.1 Biosimilar Epoetin in the EU 2006-2013
7.3.1.1 Pipeline Epoetin Alpha for the EU Submarket 2014
7.3.1.2 Trends in Uptake for Biosimilar Epoetins in the EU
7.3.2 Companies Preparing for US Launch in 2015
7.3.2.1 The US Is an Appealing Submarket for Developers
7.3.3 Biosimilar Epoetin: Japanese Submarket Overview 2010-2013
7.3.4 Biosimilar Epoetins in Emerging Markets: Multiple Players in a Fragmented Market
7.3.5 Second-Generation EPO Biosimilars
7.3.5.1 Biosimilar Darbepoetin Alpha Pipeline 2014
7.3.6 Biosimilar EPO Submarket Forecast 2014-2024

8. Biosimilar G-CSF: Outlook and Forecast 2014-2024
8.1 Amgen Leads the G-CSF Submarket in 2014
8.1.1 G-CSF Submarket Outlook and Forecast 2014-2024
8.1.2 Teva Launches Long-Acting Pegfilgrastim
8.1.2.1 Other Long-Acting Therapies in Development
8.2 The Biosimilar G-CSF Submarket 2014
8.2.1 One of the First Biosimilars in the EU and US
8.2.1.1 Zarzio Is the Most Prescribed Filgrastim Therapy in Europe
8.2.1.2 Tevagrastim: The First EU Biosimilar
8.2.1.3 Nivestim (Hospira)
8.2.2 Multiple Launches in Japan 2013-2014
8.2.3 Biosimilar Pegfilgrastim and Filgrastim in Emerging Markets
8.2.3.1 A Competitive Biosimilar Submarket in Russia
8.3 Biosimilar G-CSF Submarket 2014-2024
8.3.1 Biosimilar G-CSF Submarket Forecast 2014-2024
8.3.2 Biosimilar G-CSF Submarket: US Launches to Drive Growth 2014-2024
8.3.3 Trends in Biosimilar Uptake in the EU 2008-2013
8.3.4 Biosimilars Targeting the US Submarket
8.4 Biosimilar Pegfilgrastim: Pipeline 2014
8.4.1 Sandoz Leads the Way for Developed Markets
8.4.2 Hospira Gains Funding for Parallel Filgrastim and Pegfilgrastim Development

9. Biosimilar Interferons Submarket 2014-2024
9.1 Steady Growth in the Interferon Alpha and Beta Submarkets 2011-2013
9.1.1 Many Challengers Exist in the Multiple Sclerosis Market
9.1.2 All-Oral Regimens Will Challenge Interferon Alpha Therapy
9.1.2.1 Oral Therapies Will be High Cost
9.2 Interferon Submarket Forecast: Falling Revenue to 2024
9.3 Biosimilar Interferon Submarket 2013
9.3.1 There Are No Biosimilars Approved in Developed Markets
9.3.2 Biosimilar Interferon Submarket Forecast 2014-2024
9.4 Biosimilar Interferon Alpha 2014-2024
9.4.1 Biosimilar Interferon Alpha Is a Common Target in BRIC Nations
9.4.2 Biosimilar Peginterferon Alpha Pipeline 2014
9.4.3 Hepatitis Is a Growing Problem in Emerging Markets
9.4.4 Biosimilar Interferon Alpha Submarket Forecast 2014-2024
9.5 Biosimilar Interferon Beta 2014-2024
9.5.1 Biosimilars Are Well-Established in Emerging Markets
9.5.1.1 Biosimilar Interferon Beta Pipeline 2014
9.5.2 Will EMA Guidance Drive Development in the EU?
9.5.3 Long-Acting Interferon Beta to Launch in 2014
9.5.4 Biosimilar Interferon Beta Submarket Forecast 2014-2024

10. Recombinant Hormones: Biosimilar Submarket Outlook 2014-2024
10.1 Biosimilar Growth Hormones Submarket 2014-2024
10.1.1 Novo Nordisk and Pfizer Dominate the Growth Hormones Submarket
10.1.2 Product Lifecycle Management Will Maintain Revenues for Submarket Leaders 2014-2024
10.1.3 Biosimilar Growth Hormone Submarket 2013
10.1.3.1 Omnitrope: The World’s Bestselling Biosimilar
10.1.4 Many Biosimilars Are Available Worldwide
10.1.4.1 Biosimilar Growth Hormones in Japan and China
10.1.5 Biosimilar Uptake Varies by Region
10.1.6 Biosimilar Growth Hormone Submarket Forecast 2014-2024
10.2 Biosimilar Fertility Hormones Submarket 2014-2024
10.2.1 Two Products Lead the Fertility Hormone Submarket 2014
10.2.2 Long-Acting Follicle-Stimulating Hormone (FSH)
10.2.3 Fertility Hormone Submarket Forecast 2014-2024
10.2.4 Biosimilar Fertility Hormones 2014-2024
10.2.4.1 Two Biosimilars Approved in the EU 2013-2014
10.2.4.2 Biosimilars Beyond FSH 2014
10.2.5 Biosimilar Fertility Hormone Submarket Forecast 2014-2024
10.2.6 Rising Infertility to Drive Demand to 2024

11. Biosimilars and Follow-On Biologics: Industry Trends 2014-2024
11.1 Biosimilars Market: Strengths 2014
11.1.1 Biosimilars Are Available and Well-Established in Many National Markets
11.1.2 Leading Classes of Biological Drug Face Biosimilar Competition
11.1.3 Biosimilars Offer Cost Savings
11.1.4 Outsourcing Offers the Chance for Further Cost Savings
11.2 Biosimilars Market: Weaknesses 2014
11.2.1 Uptake for Most Biosimilars Remains Low in 2014
11.2.2 Biosimilars Are High Cost to Develop and Manufacture
11.2.3 Development Timelines for Biosimilars Are Long
11.2.4 Few Companies Dominate the Late-Stage Pipeline
11.2.5 Awareness of Biosimilars Remains Low
11.3 Biosimilars Market: Opportunities 2014-2024
11.3.1 The Pipeline for New Biosimilars Is Long
11.3.2 Blockbuster Biologics Face Patent Expiry
11.3.3 Rising Disease Chronic Disease Prevalence
11.3.4 Licensing Agreements for Biosimilars
11.3.5 The Opportunity for Biosimilar Substitution?
11.4 Biosimilars Market: Threats 2014-2024
11.4.1 The Threat of Biobetters and Next-Generation Biologics
11.4.2 Product Lifecycle Management to Extend Branded Revenues
11.4.3 Many Companies Are Chasing the Same Targets
11.4.4 Long Market and Data Exclusivity Periods Will Slow Biosimilar Development
11.4.5 Biosimilars Require Marketing
11.5 Porter’s Five Forces Analysis for the Biosimilars Market 2014-2024
11.5.1 Rivalry Among Competitors
11.5.2 Threat of New Entrants
11.5.3 Bargaining Power of Suppliers
11.5.4 Bargaining Power of Buyers
11.5.5 Threat of Substitutes

12. Research Interviews
12.1 Dr Don Stewart, CEO, PlantForm
12.1.1 Benefits in Plant-Based Systems
12.1.1.1 PlantForm Uses Tobacco Plants
12.1.2 Technological Challenges in Plant-Based Systems
12.1.3 Developing Biosimilars for North America and Europe
12.1.4 Differentiating Biosimilar Antibodies
12.1.5 The Threat of Biobetters
12.1.6 PlantForm’s Biosimilar Development
12.1.7 Biosimilar Development for Emerging Markets
12.2 Biosidus
12.2.1 Current Biosimilars Business and Product Portfolio
12.2.2 Regional Competition Facing Biosidus
12.2.3 Future Strategies for Growth and Company Threats

13. Conclusions of the Research and Analysis
13.1 The Biosimilars Market Will Grow Strongly to 2024
13.2 Biosimilar MAb Development Will Lead the Market
13.3 Rising Costs Will Drive Demand for Biosimilars
13.4 Challenges Remain in Developing and Successfully Launching Biosimilars



List of Tables
Table 1.1 Currency Exchange Rates
Table 1.2 First Approvals for Recombinant Protein Therapies, 1982-1993
Table 2.1 Biosimilars Market: Revenues ($bn), 2010-2013
Table 2.2 Biologics Market: Revenues ($bn) and Market Shares (%) by Sector, 2013
Table 2.3 Top 10 Biologics by Revenue ($bn), 2013
Table 2.4 Biosimilars Market: Revenues ($bn) and Market Shares (%) by Sector, 2013
Table 2.5 Biologics Market: Overall Market Forecast and Revenue Forecasts ($bn) by Sector, 2013, 2018, 2024
Table 2.6 Biosimilars Market: Overall Market Forecast and Revenue Forecasts ($bn) by Sector, 2013-2024
Table 2.7 Biosimilars: Market Shares (%) by Sector, 2013-2024
Table 3.1 Biosimilars Market: Revenues ($bn) and Market Shares (%) by Region, 2013
Table 3.2 Biosimilars Market: Overall Market Forecast and Revenue Forecasts ($bn) by Region, 2013-2024
Table 3.3 Biosimilars: Market Shares (%) by Region, 2013-2024
Table 3.4 First Time Approvals for Leading Biosimilar Classes in the US, 2006-2028
Table 3.5 US Biosimilars Submarket Forecast ($bn), 2013-2024
Table 3.6 EU Biosimilar Approvals, 2006-2014
Table 3.7 EU Biosimilars Submarket: Revenues ($bn) and Market Shares (%) by Leading Country, 2013
Table 3.8 EU Biosimilars Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn) by Leading Country, 2013-2024
Table 3.9 German Biosimilars Submarket Forecast ($bn), 2013-2024
Table 3.10 French Biosimilars Submarket Forecast ($bn), 2013-2024
Table 3.11 UK Biosimilars Submarket Forecast ($bn), 2013-2024
Table 3.12 Italian Biosimilars Submarket Forecast ($bn), 2013-2024
Table 3.13 Spanish Biosimilars Submarket Forecast ($bn), 2013-2024
Table 3.14 Japanese Biosimilar Development Collaborations, 2010-2014
Table 3.15 Japanese Biosimilars Submarket Forecast ($bn), 2013-2024
Table 4.1 Biosimilars Market: Revenues ($bn) and Market Shares (%) for Emerging Markets, 2013
Table 4.2 Biosimilars Market: Overall Market Forecast and Revenue Forecasts ($bn) for Top Emerging Markets, 2013-2024
Table 4.3 Chinese Biosimilars Submarket Forecast ($bn), 2013-2024
Table 4.4 Indian Biosimilars Submarket Forecast ($bn), 2013-2024
Table 4.5 Brazilian Biosimilars Submarket Forecast ($bn), 2013-2024
Table 4.6 Russian Biosimilars Submarket Forecast ($bn), 2013-2024
Table 4.7 South Korean Biosimilars Submarket Forecast ($bn), 2013-2024
Table 5.1 MAbs and FPs Submarket: Revenues ($bn) and Submarket Shares (%) by Drug, 2013
Table 5.2 Top 20 MAbs and FPs: Main Indications, 2014
Table 5.3 MAbs and FPs: Submarket Forecast ($bn), 2013-2024
Table 5.4 Types of Next-Generation Antibody Therapy, 2014
Table 5.5 Approved Biosimilar MAbs and FPs, 2014
Table 5.6 Biosimilar MAbs and FPs Submarket: Revenues ($bn) and Submarket Shares (%) by Sector, 2013
Table 5.7 Biosimilar MAbs and FPs Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn) by Sector, 2013-2024
Table 5.8 Biosimilar MAbs and FPs Submarket: Drivers and Restraints, 2014-2024
Table 5.9 Reditux: Revenue ($m), 2008-2013
Table 5.10 Biosimilar Rituximab: Revenue Forecast ($bn), 2013-2024
Table 5.11 Biosimilar Rituximab: Clinical and Commercial Pipeline, 2014
Table 5.12 Biosimilar Infliximab: Revenue Forecast ($bn), 2013-2024
Table 5.13 Biosimilar Infliximab: Clinical and Commercial Pipeline, 2014
Table 5.14 Biosimilar Trastuzumab: Revenue Forecast ($bn), 2013-2024
Table 5.15 Biosimilar Trastuzumab: Clinical and Commercial Pipeline, 2014
Table 5.16 Biosimilar Adalimumab: Revenue Forecast ($bn), 2013-2024
Table 5.17 Biosimilar Adalimumab: Clinical and Commercial Pipeline, 2014
Table 5.18 Fusion Proteins: Revenues ($bn) and Submarket Shares (%) by Drug, 2013
Table 5.19 Biosimilar Etanercept: Revenue Forecast ($bn), 2013-2024
Table 5.20 Biosimilar Etanercept: Clinical and Commercial Pipeline, 2014
Table 6.1 Insulin Submarket: Revenues ($bn) and Submarket Shares (%) by Sector, 2013
Table 6.2 Insulin Submarket Forecast ($bn), 2013-2024
Table 6.3 Diabetes Prevalence in Leading National Markets, 2014
Table 6.4 Selected Insulin Biosimilars Approved and Launched in Emerging Markets, 2014
Table 6.5 Biosimilar Insulin Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn) by Sector, 2013-2024
Table 6.6 Biosimilar Insulin Submarket: Drivers and Restraints, 2014-2024
Table 6.7 Biosimilar Human Insulin Submarket: Revenues ($bn) and Submarket Share (%) by Product, 2013
Table 6.8 Biosimilar Human Insulin Submarket Forecast ($bn), 2013-2024
Table 6.9 Biosimilar Insulin Analogues Submarket: Revenues ($bn) and Submarket Shares (%) by Sector, 2013
Table 6.10 Insulin Analogues Submarket: Revenues ($bn) and Submarket Share (%) by Product, 2013
Table 6.11 Biosimilar Insulin Analogues Submarket Forecast ($bn), 2013-2024
Table 6.12 Biosimilar Insulin Glargine: Revenue Forecast ($bn), 2013-2024
Table 6.13 Biosimilar Insulin Glargine: Clinical and Commercial Pipeline, 2014
Table 6.14 Biosimilar Insulin Lispro: Revenue Forecast ($bn), 2013-2024
Table 6.15 Ultra-Rapid Acting Insulin: Pre-Clinical and Clinical-Stage Pipeline, 2014
Table 7.1 EPO Submarket: Revenues ($bn) and Submarket Shares (%) by Product, 2013
Table 7.2 Aranesp and Procrit: Falling Revenue ($bn), 2011-2013
Table 7.3 EPO Submarket Forecast ($bn), 2013-2024
Table 7.4 Japanese Epoetin Alpha Submarket: Revenues ($bn) by Drug, 2010-2013
Table 7.5 Selected EPO Biosimilars Approved in India, 2014
Table 7.6 EPIAO: Revenue ($bn), 2008-2012
Table 7.7 Biosimilar EPO Submarket Revenue Forecast ($bn), 2013-2024
Table 7.8 Biosimilar EPO Submarket: Drivers and Restraints, 2014-2024
Table 8.1 G-CSF Submarket: Revenues ($bn) and Submarket Shares (%) by Product, 2013
Table 8.2 G-CSF Submarket Forecast ($bn), 2013-2024
Table 8.3 Selected Filgrastim Biosimilars Approved Worldwide, 2014
Table 8.4 Biosimilar G-CSF Submarket Forecast ($bn), 2013-2024
Table 8.5 Biosimilar G-CSF Submarket: Drivers and Restraints, 2014-2024
Table 9.1 Branded Interferon Therapies Approved, 2014
Table 9.2 Interferons Submarket: Revenues ($bn) by Sector, 2011-2013
Table 9.3 Interferons Submarket Forecast ($bn), 2013-2024
Table 9.4 Biosimilar Interferons Submarket: Revenues ($bn) and Submarket Shares (%) by Sector, 2013
Table 9.5 Biosimilar Interferons Submarket: Drivers and Restraints, 2014-2024
Table 9.6 Biosimilar Interferons Submarket: Overall Submarket Forecast and Revenue Forecasts ($bn) by Sector, 2013-2024
Table 9.7 Selected Interferon Alpha Biosimilars Approved Worldwide, 2014
Table 9.8 Chronic Hepatitis B and C: Global Prevalence by Region, 2014
Table 9.9 Biosimilar Interferon Alpha Submarket Forecast ($bn), 2013-2024
Table 9.10 Selected Interferon Alpha Biosimilars Approved Worldwide, 2014
Table 9.11 Biosimilar Interferon Beta Submarket Forecast ($bn), 2013-2024
Table 10.1 Growth Hormones Submarket: Revenues ($bn) and Submarket Shares (%) by Product, 2013
Table 10.2 Growth Hormones Submarket Forecast ($bn), 2013-2024
Table 10.3 Biosimilar Growth Hormones Submarket: Revenues ($bn) and Submarket Shares (%) by Product, 2013
Table 10.4 Biosimilar Growth Hormones Submarket Forecast ($bn), 2013-2024
Table 10.5 Biosimilar Growth Hormones Submarket: Drivers and Restraints, 2014-2024
Table 10.6 Fertility Hormones Submarket: Revenues ($bn) and Submarket Shares (%) by Product, 2013
Table 10.7 Fertility Hormones Submarket Forecast ($bn), 2013-2024
Table 10.8 Biosimilar Fertility Hormones Submarket Forecast ($bn), 2013-2024
Table 10.9 Biosimilar Fertility Hormones Submarket: Drivers and Restraints, 2014-2024
Table 11.1 World Biosimilars Market: Strengths, Weaknesses, Opportunities and Threats (SWOT), 2014-2024
Table 11.2 EMA Sector-Specific Biosimilar Guidelines, 2006-2013
Table 11.3 National Incidence and Prevalence of Leading Indications Treated with Biologics, 2014
Table 11.4 Prominent Biosimilar Collaborations, 2010-2014
Table 11.5 Next-Generation Biologics Developments, 2007-2018
Table 13.1 Biosimilars Market: Submarket Forecasts ($bn) and Market Shares (%), 2013, 2018, 2024


List of Figures
Figure 2.1 Biosimilars Market: Revenues ($bn), 2010-2013
Figure 2.2 Biologics Market Shares (%) by Sector, 2013
Figure 2.3 Biosimilars Market Shares (%) by Sector, 2013
Figure 2.4 Biologics Market: Revenue Forecast ($bn), 2013-2024
Figure 2.5 Biosimilars Market: Revenue Forecast ($bn), 2013-2024
Figure 2.6 Biosimilars Market Shares (%) by Sector, 2018
Figure 2.7 Biosimilars Market Shares (%) by Sector, 2024
Figure 2.8 Biosimilars Market Drivers, 2014-2024
Figure 2.9 Biosimilars Market Restraints, 2014-2024
Figure 3.1 Biosimilars Market Shares (%) by Region, 2013
Figure 3.2 Biosimilars Market Shares (%) by Region, 2013-2024
Figure 3.3 US Biosimilars Submarket Forecast ($bn), 2013-2024
Figure 3.4 Biosimilars Submarket: Submarket Shares (%) for EU5 Countries, 2013
Figure 3.5 EU Biosimilars Submarket Forecast ($bn), 2013-2024
Figure 3.6 German Biosimilars Submarket Forecast ($bn), 2013-2024
Figure 3.7 French Biosimilars Submarket Forecast ($bn), 2013-2024
Figure 3.8 UK Biosimilars Submarket Forecast ($bn), 2013-2024
Figure 3.9 Italian Biosimilars Submarket Forecast ($bn), 2013-2024
Figure 3.10 Spanish Biosimilars Submarket Forecast ($bn), 2013-2024
Figure 3.11 Japanese Biosimilars Submarket Forecast ($bn), 2013-2024
Figure 4.1 Biosimilars Market: Emerging Nation Market Shares (%), 2013
Figure 4.2 Chinese Biosimilars Submarket Forecast ($bn), 2013-2024
Figure 4.3 Indian Biosimilars Submarket Forecast ($bn), 2013-2024
Figure 4.4 Brazilian Biosimilars Submarket Forecast ($bn), 2013-2024
Figure 4.5 Russian Biosimilars Submarket Forecast ($bn), 2013-2024
Figure 4.6 South Korean Biosimilars Submarket Forecast ($bn), 2013-2024
Figure 5.1 MAbs and FPs Submarket Shares (%) by Drug, 2013
Figure 5.2 Top 20 MAbs and FPs: Main Indications, 2014
Figure 5.3 MAbs and FPs Submarket Forecast ($bn), 2013-2024
Figure 5.4 MAbs and FPs Submarket Shares (%) by Sector, 2013
Figure 5.5 Biosimilar MAbs and FPs Submarket Forecast ($bn), 2013-2024
Figure 5.6 Reditux: Revenue ($m), 2008-2013
Figure 5.7 Biosimilar Rituximab: Revenue Forecast ($bn), 2013-2024
Figure 5.8 Biosimilar Infliximab: Revenue Forecast ($bn), 2013-2024
Figure 5.9 Biosimilar Trastuzumab: Revenue Forecast ($bn), 2013-2024
Figure 5.10 Biosimilar Adalimumab: Revenue Forecast ($bn), 2013-2024
Figure 5.11 Biosimilar Etanercept: Revenue Forecast ($bn), 2013-2024
Figure 6.1 Insulin Submarket Shares (%) by Sector, 2013
Figure 6.2 Insulin Submarket Forecast ($bn), 2013-2024
Figure 6.3 Diabetes Prevalence in Leading National Markets, 2014
Figure 6.4 Biosimilar Insulin Submarket Forecast ($bn), 2013-2024
Figure 6.5 Biosimilar Human Insulin: Submarket Shares (%) by Product, 2013
Figure 6.6 Biosimilar Human Insulin Submarket Forecast ($bn), 2013-2024
Figure 6.7 Biosimilar Insulin Analogues: Submarket Shares (%) by Sector, 2013
Figure 6.8 Insulin Analogues: Submarket Shares (%) by Product, 2013
Figure 6.9 Biosimilar Insulin Analogues Submarket Forecast ($bn), 2013-2024
Figure 6.10 Biosimilar Insulin Glargine: Revenue Forecast ($bn), 2013-2024
Figure 6.11 Biosimilar Insulin Lispro: Revenue Forecast ($bn), 2013-2024
Figure 7.1 EPO Submarket Shares (%) by Product, 2013
Figure 7.2 Aranesp and Procrit: Falling Revenue ($bn), 2011-2013
Figure 7.3 EPO Submarket Forecast ($bn), 2013-2024
Figure 7.4 Japanese Epoetin Alpha Submarket: Revenues ($bn) by Drug, 2010-2013
Figure 7.5 EPIAO: Revenue ($bn), 2008-2012
Figure 7.6 Biosimilar EPO Submarket Forecast ($bn), 2013-2024
Figure 8.1 G-CSF Submarket Shares (%) by Product, 2013
Figure 8.2 G-CSF Submarket Forecast ($bn), 2013-2024
Figure 8.3 Biosimilar G-CSF Submarket Forecast ($bn), 2013-2024
Figure 9.1 Interferons Submarket: Revenues ($bn) by Sector, 2011-2013
Figure 9.2 Interferons Submarket Forecast ($bn), 2013-2024
Figure 9.3 Biosimilar Interferons: Submarket Shares (%) by Sector, 2013
Figure 9.4 Biosimilar Interferons Submarket: Revenue Forecast ($bn), 2013-2024
Figure 9.5 Chronic Hepatitis B and C: Global Prevalence by Region, 2014
Figure 9.6 Biosimilar Interferon Alpha Submarket Forecast ($bn), 2013-2024
Figure 9.7 Biosimilar Interferon Beta Submarket Forecast ($bn), 2013-2024
Figure 10.1 Growth Hormones Submarket Shares (%) by Product, 2013
Figure 10.2 Growth Hormones Submarket Forecast ($bn), 2013-2024
Figure 10.3 Biosimilar Growth Hormones Submarket Shares (%) by Product, 2013
Figure 10.4 Biosimilar Growth Hormones Submarket Forecast ($bn), 2013-2024
Figure 10.5 Fertility Hormones Submarket Shares (%) by Product, 2013
Figure 10.6 Fertility Hormones Submarket Forecast ($bn), 2013-2024
Figure 10.7 Biosimilar Fertility Hormones Submarket Forecast ($bn), 2013-2024
Figure 11.1 Biosimilar Development Costs by Stage, 2014
Figure 11.2 Biosimilar Development Timeline by Stage, 2014
Figure 11.3 Bestselling Biologics Facing Patent Expiry 2014-2019
Figure 11.4 Porter’s Five Forces Analysis of the Biosimilars Market, 2014-2024
Figure 13.1 Biosimilars Market: Submarket Forecasts ($bn), 2013, 2018, 2024

【掲載企業】

3SBio
AbbVie
Aché
Actavis
Adocia
AET BioTech
Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) [France]
Agência Nacional de Vigilância Sanitária (ANVISA) [Brazil]
Agenzia Italiana del Farmaco (AIFA)
Agila Biotech (part of Strides Arcolab)
Alliance for Safe Biologic Medicines (ASBM)
Allozyne
Alteogen
Alvogen
Amarey Nova Medical
Ambrx
Amega Biotech
Amgen
Antares Pharma
Apotex
Aprogen
Aryogen Biopharma
Astellas Pharma
AstraZeneca
Avesthagen
Baxter International
Bayer
Beijing Four Rings Pharmaceutical
Beijing SL Pharmaceutical
Binex Co.
Biocad
Bioceuticals Arzneimittel (part of Stada)
Biocon
Biodel
Biogen Idec
BioGeneriX (part of Teva)
BioGenomics
Biolab Sanus Farmacêutica
Bionovis
Biopartners (part of Bioton)
Biosidus
Bioton
Boehringer Ingelheim
Brazilian Ministry of Health
Bristol-Myers Squibb
Cardiovascular and Renal Drugs Advisory Committee [US]
CCL Pharmaceuticals
CCM Duopharma Biotech
Celltrion
Centers of Medicare and Medicaid Services (CMS)
Central Drugs Standard Control Organisation (CDSCO) [India]
China Food and Drug Administration (CFDA)
Chong Kun Dang
Chugai Pharmaceutical (part of Roche)
CinnaGen
Cipla
Coherus BioSciences
Comisión Federal para la Protección contra Riesgos Sanitarios (Cofepris) [Mexico]
Compass Biotechnologies
CT Arzneimittel (part of Teva)
Daewoong Pharmaceutical
Daiichi Sankyo
Dance Biopharm
Dem Pharmaceuticals
Department of Biotechnology [India]
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Drug Controller General of India (DCGI)
Drug Regulatory Authority of Pakistan (DRAP)
Egis Pharmaceuticals
Eli Lilly
Elpen Pharmaceutical
EMA Committee for Medicinal Products for Human Use (CHMP) [EU]
Emcure Pharmaceuticals
EMS
Epirus Biopharmaceuticals
Eurofarma Laboratórios
European Commission
European Medicines Agency (EMA)
Europharm
EvaluatePharma (now Evaluate)
Express Scripts
FDA Center for Drug Evaluation and Research (CDER) [US]
FibroGen
Finox
Fuji Pharma
Fujifilm
Fujifilm Kyowa Kirin Biologics
Gan & Lee Pharmaceutical
Gedeon Richter
Gene Techno Science
Genentech (part of Roche)
International Biotech Center Generium (Generium)
Genexine
Gennova Biopharmaceuticals (part of Emcure Pharmaceuticals)
GeneScience Pharmaceuticals (GenSci)
Genzyme (part of Sanofi)
Geropharm
Gilead Sciences
GlaxoSmithKline (GSK)
Halozyme Therapeutics
Hangzhou Jiuyuan Gene Engineering
Hanmi Pharmaceutical
Hanwha Chemical
Haselmeier
Health Canada
Henlius Biotech
Hexal (part of Novartis)
Hikma Pharmaceuticals
Hindustan Anti Biotech
Hospira
Hualida Biotech
Hypermarcas
IGES Institut [Germany]
Innovare R&D
Insmed
Instituto Vital Brazil
Intas Biopharmaceuticals
Intellectual Property Appellate Board (IPAB) [India]
International Diabetes Federation (IDF)
inVentiv Health
Isu Abxis
Johnson & Johnson (J&J)
JCR Pharmaceuticals
Kemwell Biopharma
Kissei Pharmaceutical
Koçak Farma
Kwizda Pharma
Kyowa Hakko Kirin
Laboratorios Delta
Landsteiner Scientific
LG Life Sciences
Libbs Farmacêutica
LMC
Lonza
Mabion
mAbxience
MannKind
Marvel Life Sciences
Medice
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Merck & Co.
Merck Serono
Minapharm Pharmaceuticals
Ministry of Food and Drug Safety (MFDS) [South Korea]
Ministry of Health and Medical Education [Iran]
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
Mochida Pharmaceutical
Momenta Pharmaceuticals
Mycenax Biotech
Mylan
National Health Service (NHS) [UK]
National Institute for Health and Care Excellence (NICE) [UK]
National Institute for the Control of Pharmaceutical and Biological Products [China]
Nichi-Iko Pharmaceutical
Nippon Kayaku
Norwegian Ministry of Health
NovaQuest Capital Management
Novartis
Novo Nordisk
Nuron Biotech
Oncobiologics
OPKO Health
Organon (part of Merck & Co.)
Ortho Pharmaceutical (now Janssen Pharmaceuticals)
Orygen Biotecnologia
PanGen Biotech
Parexel International
Pfenex
Pfizer
Pharmapark (part of Pharmstandard)
PharmaPraxis
Pharmstandard
PlantForm
Pliva (part of Teva)
PRA International
Pro Generika [Germany]
Probiomed
Prolor Biotech (part of OPKO Health)
Qilu Pharmaceutical
Quintiles
Ranbaxy Laboratories
ratiopharm (part of Teva)
Regeneron Pharmaceuticals
Reliance GeneMedix (part of Reliance Life Sciences)
Reliance Life Sciences
Rentschler Biotechnologie
Roche
Russian Ministry of Health
SAFC
Samsung
Samsung Bioepis
Samsung BioLogics
Sandoz (part of Novartis)
Sanofi
Sanwa Kagaku Kenkyusho
SciGen (part of Bioton)
Scottish Medicines Consortium (SMC)
Seattle Genetics
Shandong Kexing Bioproducts
Shanghai Celgen Biopharmaceutical
Shanghai CP Guojian Pharmaceutical
Shanghai Fosun Pharmaceutical
Shantha Biotechnics
Sicor Biotech (part of Teva)
Sothema Laboratories
Spectrum Pharmaceuticals
Stada Arzneimittel
Stanford University
State Employees’ Social Security and Social Services Institute (ISSSTE) [Mexico]
Stragen Pharma
Strides Arcolab
Syngene International
Synthon Biopharmaceuticals
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries
The United Laboratories
Therapeutic Goods Administration (TGA) [Australia]
Thermalin Diabetes
Tianjin Hualida Biotechnology
Tonghua Dongbao
University of Toronto
TSH Pharma
UMN Pharma
União Química
University of California, Los Angeles (UCLA)
University of California, San Francisco (UCSF)
US Centers for Disease Prevention and Control (CDC)
US Food and Drug Administration (FDA)
US Patent and Trademark Office (USPTO)
USV Biologics
Virchow Biotech
Wangbang Biopharmaceuticals (part of Shanghai Fosun)
Wockhardt
World Bank Group
World Cancer Research Fund (WCRF)
World Health Organization (WHO)
Xeris Pharmaceuticals
Xiamen Amoytop Biotech
Yakult Honsha
Ypsomed
Zenotech Laboratories
Zhejiang Huahai Pharmaceutical
Zuventus Healthcare (part of Emcure Pharmaceuticals)
Zydus Cadila

★調査レポート[世界におけるバイオシミラー及び後続生物製剤市場(2014-2024)] ( Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 / Visiongain-4052662) 販売に関する免責事項
[世界におけるバイオシミラー及び後続生物製剤市場(2014-2024)] ( Biosimilars and Follow-On Biologics: World Industry and Market Prospects 2014-2024 / Visiongain-4052662) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆